Pablo Corral/LinkedIn
Nov 9, 2025, 01:51
Pablo Corral: A True Game Changer in Lipid Management
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”AHA 2025 | CORALreef Lipids Trial
A true game changer in lipid management.
Enliciditide (MK-0616) – the first oral PCSK9 inhibitor – achieved a 57% LDL-C reduction at week 24 and – 50% sustained at week 52 vs placebo (p<0.001).
- Phase 3 trial, 2,912 patients with ASCVD or at high risk, across 14 countries, with excellent safety profile.
- Takeaway: efficacy and safety comparable to injectable PCSK9 inhibitors — but in a once-daily oral tablet.
- A new era in PCSK9 inhibition and cardiovascular prevention.”
Stay updated with Hemostasis Today.
-
Dec 15, 2025, 06:19Atrial Fibrillation in World-Class Rowers․ Beyond Traditional Risk Factors
-
Dec 15, 2025, 06:18AF Ablation and Anticoagulation․ Can We Stop Treatment?
-
Dec 14, 2025, 16:06Dr Abdul Mannan: What’s Your Approach to Diagnosing Iron Deficiency in Tricky Cases?
-
Dec 14, 2025, 16:05Mark Young – 46 Shadow Gates: How Your Chromosomes Archive Ancestral Memory
-
Dec 14, 2025, 16:04NNHF Unveiled at ASH2025: a Bold New Chapter was Marked – Expanding Beyond Haemophilia Care to Include SCD and Thalassemia
-
Dec 14, 2025, 15:46Heghine Khachatryan about PVCS as Cause of Chronic Pelvic Pain and Lower-Extremity/Pelvic Varices in Women
-
Dec 14, 2025, 15:42Gianluca Franceschini – Prevention is the Future: Investing Today to Save Lives Tomorrow
-
Dec 14, 2025, 13:55Indunil Karunarathna: Anticoagulation Therapy in Atrial Fibrillation Risks and Benefits
-
Dec 14, 2025, 12:56Mentored by Riten Kumar, Sriveda Boyalakuntla Presents Key Research on Infection-Associated Thrombosis at ASH25